Kris Capper, Benjamin McGettigan, Cate Willis, Brittany Stevenson
{"title":"Omalizumab enables bee venom desensitisation in patients with anaphylactic reactions to venom immunotherapy.","authors":"Kris Capper, Benjamin McGettigan, Cate Willis, Brittany Stevenson","doi":"10.1016/j.jaip.2025.09.038","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Venom immunotherapy (VIT) is the only treatment for honeybee venom allergy; however, some patients develop severe allergic reactions (SAR) during therapy. Omalizumab, an anti-IgE antibody, may improve VIT tolerance, though data in honeybee VIT remain limited.</p><p><strong>Objective: </strong>To evaluate the efficacy of adjuvant omalizumab in honeybee VIT, identify predictors of omalizumab requirement, and inform protocol selection.</p><p><strong>Methods: </strong>A retrospective chart review was conducted of all adults undergoing honeybee VIT at Fiona Stanley Hospital, Perth, Western Australia, from 2015 to 2024. Baseline characteristics, biomarkers, protocols, and outcomes were analysed.</p><p><strong>Results: </strong>Among 354 VIT patients, 57 (16%) experienced SARs, with 36 (10%) receiving omalizumab. Predictors of omalizumab need included severe sting anaphylaxis, asthma, and elevated basal tryptase. One patient used omalizumab to escalate VIT dosing after already reaching maintenance. Of 35 patients using omalizumab during VIT up-titration, 22 (63%) achieved unsupported maintenance, 7 (20%) ceased due to SARs, and 5 (14%) remain on omalizumab. Excluding 5 patients who declined or lacked access to ongoing omalizumab, the success rate increases to 73%. The most common protocol involved a 12-week VIT up-titration to 100 μg with omalizumab 300 mg loading 2 weeks prior, followed by 150 mg fortnightly until maintenance VIT was reached. SARs most frequently occurred at omalizumab cessation. In 3 cases, these were overcome by resuming omalizumab with a higher VIT maintenance dose target.</p><p><strong>Conclusion: </strong>Omalizumab could be considered in patients experiencing recurrent SARs to standard VIT. A semi-rush protocol with omalizumab loading 1 to 2 weeks prior was well tolerated.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaip.2025.09.038","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Venom immunotherapy (VIT) is the only treatment for honeybee venom allergy; however, some patients develop severe allergic reactions (SAR) during therapy. Omalizumab, an anti-IgE antibody, may improve VIT tolerance, though data in honeybee VIT remain limited.
Objective: To evaluate the efficacy of adjuvant omalizumab in honeybee VIT, identify predictors of omalizumab requirement, and inform protocol selection.
Methods: A retrospective chart review was conducted of all adults undergoing honeybee VIT at Fiona Stanley Hospital, Perth, Western Australia, from 2015 to 2024. Baseline characteristics, biomarkers, protocols, and outcomes were analysed.
Results: Among 354 VIT patients, 57 (16%) experienced SARs, with 36 (10%) receiving omalizumab. Predictors of omalizumab need included severe sting anaphylaxis, asthma, and elevated basal tryptase. One patient used omalizumab to escalate VIT dosing after already reaching maintenance. Of 35 patients using omalizumab during VIT up-titration, 22 (63%) achieved unsupported maintenance, 7 (20%) ceased due to SARs, and 5 (14%) remain on omalizumab. Excluding 5 patients who declined or lacked access to ongoing omalizumab, the success rate increases to 73%. The most common protocol involved a 12-week VIT up-titration to 100 μg with omalizumab 300 mg loading 2 weeks prior, followed by 150 mg fortnightly until maintenance VIT was reached. SARs most frequently occurred at omalizumab cessation. In 3 cases, these were overcome by resuming omalizumab with a higher VIT maintenance dose target.
Conclusion: Omalizumab could be considered in patients experiencing recurrent SARs to standard VIT. A semi-rush protocol with omalizumab loading 1 to 2 weeks prior was well tolerated.
期刊介绍：
JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases.
This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders.
The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
